Breast Cancer
Conference Coverage
Capecitabine maintenance improved DFS, not OS, in TNBC patients
The 5-year disease-free survival rate was 83% in the capecitabine arm and 73% in the observation arm.
Conference Coverage
PPI added to chemo improves breast tumor response rate
Conference Coverage
Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancer
Patients with triple-negative breast cancers with PD-L1 combined positive score higher than 10 had better progression-free survival with...
Conference Coverage
Active cancer increases death risk in patients with COVID-19
Conference Coverage
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBC
Ipatasertib provided a “clinically meaningful,” but not statistically significant, 9-month improvement in median overall survival.
Feature
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
From the Journals
Mammography cuts risk for fatal breast cancers: New data
A large study showed a survival benefit from mammography, but an expert questioned the study’s methodology.
From the Journals
COVID-19 death rate was twice as high in cancer patients in NYC study
The overall case fatality rate was 28% for cancer patients with COVID-19 and 14% for noncancer COVID-19 patients.
Feature
Three months of COVID-19 may mean 80,000 missed cancer diagnoses
A backlog of 22 million canceled or postponed tests for five common cancers is expected by early June.
Feature
Cancer screening, monitoring down during pandemic
Use of some tests came to “a near standstill” in early April.
Conference Coverage
Adding a blood test to standard screening may improve early cancer detection